Reversing t cells' misunderstood rep in responding to a pediatric leukemia

June 26, 2019

A study of pediatric patients with leukemia demonstrates that they were able to generate T cells against tumor-associated mutations, contradicting previous assumptions that T cells cannot be effectively unleashed on pediatric tumors. Importantly, the findings indicate that pediatric cancers may be more vulnerable to immunotherapies such as checkpoint blockade and other T cell-targeted treatments than previously thought. Tumors often express mutant surface proteins (or neoepitopes) not found in normal cells, which can be recognized and targeted by T cells. Previous research has shown that for solid tumors, only 2% of neoepitopes elicit measurable anti-tumor responses from T cells, suggesting that tumors with a relatively low amount of mutations (such as pediatric tumors) do not provoke typical antitumor responses from the immune system and are thus not suitable candidates for immunotherapy. Seeking insight, Anthony Zamora and colleagues sequenced biopsies from nine pediatric patients with acute lymphoblastic leukemia (ALL), the most common childhood cancer. They identified five to 28 new neoepitopes per patient, and found that the patients harbored T cells that were specific to many of these neoepitopes. The authors observed that the patient T cells responded to 68% of the identified neoepitopes and formed "hierarchies" in how they responded to the mutations. Furthermore, they saw that seven of nine tested patients had T cells that responded to a single mutation called ETV6-RUNX1 that has been linked to more favorable clinical outcomes.

American Association for the Advancement of Science

Related Tumors Articles from Brightsurf:

A viable vaccine for tough tumors
While immunotherapies work well for some cancers, others are immune-resistant and condemn patients to the severe side effects of long-term chemo treatment.

Women could conceive after ovarian tumors
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.

Attacking tumors from the inside
A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.

A solid vaccine for liquid tumors
Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years.

Evolutionarily novel genes work in tumors
A team of scientists from Peter the Great St. Petersburg Polytechnic University studied the evolutionary ages of human genes and identified a new class of them expressed in tumors -- tumor specifically expressed, evolutionarily novel (TSEEN) genes.

Identification of all types of germ cells tumors
Germ cell tumors were considered very heterogeneous and diverse, until recently.

Laser light detects tumors
A team of researchers from Jena presents a groundbreaking new method for the rapid, gentle and reliable detection of tumors with laser light.

Better prognosticating for dogs with mammary tumors
For dogs with mammary tumors, deciding a course of treatment can depend on a variety of factors, some of which may seem to contradict one another.

The evolution of brain tumors
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas.

Read More: Tumors News and Tumors Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to